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Six morphine-exposed and 3 control male Indian rhesus macaques were intravenously inoculated with mixture of SHIVKU, SHIV89.6P and
SIV/17E-Fr. These animals were followed for a period of 56 weeks in order to determine CD4 and CD8 profile, viral loads in plasma and
cerebrospinal fluid (CSF), relative distribution of 3 pathogenic viruses in blood and brain, binding as well neutralizing antibody levels and cellular
immune responses. Both morphine-exposed and control macaques showed a precipitous loss of CD4+ T cells; control animals, however, showed a
greater tendency to recover these cells than did their morphine-exposed counterparts. The plasma and CSF viral loads were significantly higher in
morphine-exposed group than those in the control group. Four morphine-exposed animals succumbed to SIV/SHIV-induced AIDS at week 18, 19,
20 and 51; post-infection with neurological disorders was found in 3 of the 4 animals. At the end of the 56-week observation period, 2 morphine-
exposed and 3 control animals were still alive. All 3 viruses replicated in the blood of both morphine-exposed and control macaques, but the
cerebral compartment showed a selection phenomenon; only SIV/17E-Fr and SHIVKU successfully crossed the blood brain barrier (BBB). The
morphine-exposed macaques further favored viral migration through the blood brain barrier (BBB). SIV/17E-Fr crossed the BBB within 2 weeks
in both morphine-exposed and control macaques, whereas SHIVKU crossed the BBB more rapidly in morphine-exposed than in control macaques.
Three morphine-exposed macaques (euthanized at weeks 18, 19 and 20) did not develop cellular or humoral immune responses, whereas the other
3 morphine-exposed and 3 control macaques developed both cellular and humoral immune responses.
© 2006 Elsevier Inc. All rights reserved.Keywords: SIV; SHIV; AIDS; Indian rhesus macaques, MorphineIntroduction
Current estimates indicate that injection drug users (IDU)
constitute a large cohort among HIV-infected individuals. The
recent CDC estimate indicated that as of 2002 more than 27% of
total AIDS cases in the country were associated with IDU⁎ Corresponding author. Laboratory of Viral Immunology, Department of
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doi:10.1016/j.virol.2006.06.020(CDC, 2002). However, the natural history and progression of
HIV infection among IDU remain ambiguous (Alcabes and
Friedland, 1995; Metzger et al., 1993). According to one
prospective study, AIDS is the most frequent cause of death
among IDU (Brancato et al., 1995), but conflicting reports of
the mortality rate among HIV-infected IDU have demonstrated
both a survival advantage for HIV-infected IDU and lower
survival rates among IDU (Alcabes and Friedland, 1995;
Selwyn et al., 1992). Nevertheless, it has been clearly
demonstrated that HIV-infected IDU have substantial pre-
AIDS morbidity and mortality, particularly from bacterial
193R. Kumar et al. / Virology 354 (2006) 192–206infections, suggesting that co-infection with other pathogens
may enhance HIV expression and assist in the spread of the
disease (Eisenstein et al., 2001; Hilburger et al., 1997;
MacFarlane et al., 2000; Selwyn et al., 1992; Sepkowitz et
al., 1995; Shattock et al., 1994). This was further confirmed by a
reduction in the rate of disease progression after the cessation of
injection drug use (Ronald et al., 1994). However, the direct
evidence of a correlation between drug of abuse and increased
viral replication came from several in vitro studies, wherein
morphine and cocaine were shown to intensify both HIV and
simian immunodeficiency virus (SIV) (Peterson et al., 1990,
1991, 1992, 1993, 1994; Li et al., 2003; Chuang et al., 1993a,
1993b).
More recently, an in vivo study of an SCID mouse model of
HIV infection has shown that cocaine adversely affects the
virus replication (Roth et al., 2002; Tashkin, 2004), but the
usefulness of this model remains limited as regards the
pathogenesis and progression of the disease. The earlier studies
using a monkey model of HIV/AIDS also provided conflicting
evidence. In one set of studies, morphine dependence resulted
in an exacerbation of the SIV infection in rhesus macaques.
However, sample size in this study was too small to draw any
meaningful conclusions (Suzuki et al., 2002; Chuang et al.,
1993a, 1993b). Furthermore, the increase in virus replication in
morphine-dependent macaques was documented only
17 months after infection (Suzuki et al., 2002). In another
study, morphine dependence exerted a protective effect in an
SIVsmm9/rhesus monkey model (Donahoe et al., 1993).
However, this study lacked concurrent control animals; there-
fore, the virus replication in morphine-dependent animals was
compared with historical controls. Both of these studies, in
addition, utilized a challenge model where animals develop
relatively slower disease. With the introduction of the simian/
human immunodeficiency virus, it has been possible to develop
a model for HIV/AIDS wherein macaques not only develop a
highly productive infection in the lymphoid system (similar to
that seen in SIV infection) (Daniel et al., 1985; Nathanson et al.,
1999), but also exhibit the near total elimination of the CD4+ T
cells in blood and lymphoid tissue during acute infection
(Igarashi et al., 1999; Joag et al., 1996; Karlsson et al., 1997;
Luciw et al., 1995; Reimann et al., 1996a, 1996b, 1999). The
animals developing acute disease (i.e., AIDS within 6–
8 months) caused by pathogenic SHIV do not develop anti-
viral immune responses (Kumar et al., 2001). However, those
surviving for longer periods develop both cellular and humoral
immune responses (Kumar et al., 2001; Silverstein et al., 2000;
Stipp et al., 2000). Prolonged survival of the infected animal
has been correlated with humoral immune responses mediated
by neutralizing antibodies and cellular immune responses
mediated by CD8+ T cells. Such responses are similar to those
found in long-term non-progressors of HIV infection. In one of
our previously reported studies, the mixture of 2 SHIVs
(SHIVKU and SHIV89.6P) and a neuropathogenic SIV proved
an excellent challenge system to develop rapid and reprodu-
cible disease in the rhesus macaques (Kumar et al., 2002).
Utilizing this model, we have shown that, although chronic
morphine exposure did not alter the peak viral loads in rhesusmacaques, it caused significantly higher viral replication at
6 weeks post-infection (and thereafter) in the brain as well as
8 weeks (and thereafter) in the blood (Kumar et al., 2004).
In view of this evidence, it appears that opiates enhance
replication of HIV and SIV, and opiate dependence may, in
fact, accelerate the onset of disease. However, no in vivo
studies have been undertaken to evaluate the effect of opiate
dependence on the onset of clinical disease. In this study, we
sought to address this issue, and for the first time, we
unequivocally show that chronic morphine exposure caused
rapid onset of the disease in a majority of virus-infected
animals and compromised the development of virus-specific
immune responses in at least 50% of the morphine-exposed
animals. Two-thirds of the morphine-exposed but none of the
control animals succumbed to SIV/SHIV-induced AIDS within
51 weeks after infection.
Results
Morphine-exposed and control animals were monitored
for complete blood counts at the time of every bleeding.
None of the animals showed any significant change in any
of the different parameters except monocyte counts. The
monocyte counts in morphine-exposed animals were found to
be generally elevated; that coincided with the inception of
clinical disease. The increase ranged between 11- and 20-fold
in 4 animals (1/28Q, 1/04L, 1/42N and 1/56L), those which
developed disease within the course of the study (results not
shown).
Morphine-exposed and control macaques showed a precipitous
loss in CD4+ T cells
The morphine-exposed and control macaques were followed
in order to determine CD4, CD8 counts and CD4/CD8 ratio
throughout the 56-week observation period. The results of the
CD4+ T-cell counts and the CD4/CD8 ratio are shown in Fig. 1.
Five of the 6 morphine-exposed animals lost >95% of their
CD4+ T cells within 3 weeks after infection, and levels
remained low throughout the observation period. The 6th
animal (1/52N) showed more than a 90% loss in CD4
population at week 1 after infection; this loss was followed by
a remarkable recovery, and the macaque attained its pre-
infection level within 16 weeks. Since then, this animal has
maintained a high CD4 count throughout the observation
period. Alternately, control animals exhibited an 85–90% loss
in CD4+ T-cell numbers at week 3 followed by a reasonable
recovery in all 3 animals. One macaque (2/02P) underwent
another round of CD4 loss (starting week 12, post-infection);
this animal had maintained very low CD4 counts throughout the
study. The other two animals have maintained reasonable CD4
counts. There was no statistical difference observed between
morphine and control groups (p=0.5 and p=0.9 at weeks 8 and
18, respectively). However, the CD4 loss was highly significant
in the morphine group (after the values from macaque 1/52N
that showed substantial CD4 recovery – p=0.02 and 0.06 at
weeks 8 and 18, respectively – were excluded).
Fig. 1. CD4+ T-cell profile and CD4/CD8 ratio in morphine-exposed (A, B) and control macaques (C, D). The morphine dependence in 6 male Indian rhesus macaques
was established by injecting increasing doses of morphine (1 to 5 mg/kg body weight over 2-week period) intramuscularly, every 8 h. These animals were maintained
at 3 daily doses of morphine (5 mg/kg) for an additional 18 weeks. These animals, along with 3 unvaccinated controls, were inoculated with a mixture of SHIVKU-1B,
SHIV89.6P and SIV/17E-Fr. The CD4 and CD8 profile was determined by staining with a mixture of antibodies against CD3, CD4 and CD8. The absolute numbers of
CD4+ and CD8+ T cells were calculated by multiplying the percentage of the lymphocyte subset with the lymphocyte number and then divided by 100.
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the blood
Plasma viral loads in morphine-exposed and control groups
were determined by real-time RT-PCR (Fig. 2). Three of the 6
morphine-exposed animals (1/04L, 1/42N and 1/28Q: Group A)
showed relatively higher viral loads, with the virus titer
reaching to a level of approximately 108 RNA copies Eq/ml
in plasma. These three animals succumbed to SIV/SHIV-
induced AIDS at weeks 18, 19 and 20, respectively. Macaque 1/
04L succumbed to severe intractable chronic diarrhea and was
non-responsive to treatment, whereas 1/42N had progressive
neurological signs that included constant jerky movements,
vocalization and increased aggressiveness. Macaque 1/28Q had
a history of intermittent unilateral epistaxis and intermittent
diarrhea and was unresponsive to treatment. This animal also
showed progressive CNS signs such as increased aggressive-
ness, ataxia, jerky movements and constant drooling. All three
animals lost >30% of their body weight before they were
euthanized. The viral loads in these animals are shown in Fig.2A. Three other morphine-exposed macaques (Group B)
showed a relatively lower viral load (≥106 RNA copies Eq/ml)
in the plasma. Macaque 1/56 continued to exhibit ≥106 viral
RNA copies/ml in its plasma and succumbed to SIV/SHIV-
induced AIDS at week 51, post-infection. Clinical symptoms
at the time of necropsy included intractable chronic diarrhea,
problems with gaiting and marked weight loss. The fifth
animal (1/02N) maintained plasma viral load between 104 and
105 RNA copies/ml and was still alive with a very low CD4+
T-cell count at week 56. The last animal (1/52N) showed
remarkable CD4 recovery and was able to significantly con-
trol the viral replication; the virus became undetectable in
plasma at week 44. It remained undetectable throughout the
remainder of the observation period.
In contrast, all 3 controls (Group C) showed lower viral
replication in the blood as evident by real-time RT-PCR (Fig.
2B). Macaque 2/02P, with the highest CD4+ T-cell loss, showed
the highest virus replication, with plasma viremia ranging
between log105.5 and log 106.5 throughout the observation
period. The other two animals (2/31P and 2/AC42), with
Fig. 2. Plasma viral load in morphine-exposed (A) and control macaques (B). Sequential EDTA plasma samples were collected, and plasma viral load was determined
in a real-time RT-PCR assay. The results are presented as RNA copy Eq/ml of plasma. The sensitivity of the assay was 80 RNA copies Eq/ml.
195R. Kumar et al. / Virology 354 (2006) 192–206significant CD4 recovery, had relatively controlled virus
replication in the blood. The plasma viral loads in these animals
were 7660 and 89 copies Eq/ml at the end of the observation
period. At the time of Group A necropsy, the plasma viral load
in Group A was significantly higher (p=0.005) than that in the
Groups B and C macaques. On the other hand, Groups B and C
animals did not show significant difference in plasma viral loads
(p=0.355).
Robust virus replication in the brain preceded the onset of
clinical disease
All 9 animals were followed for viral loads in the CSF
throughout the observation period (Fig. 3). Viral replication in
the brain compartment yielded a few interesting observations.
Three control macaques (Group C) showed peak virus re-
plication between 103.5 and 104.5 followed by a gradual de-
cline; all three animals became negative within 22 weeks after
infection. Macaque 2/02P (with maximum CD4 loss) became
positive for viral RNA at week 28, and thereafter the animal
was intermittently positive with peak viral replication in the
range of 103.6 at week 44, after infection. Viral replication
in macaque 2/AC42 remained below the level of detectionuntil week 40 followed by a low level of virus replication until
the end of the study. The 3rd control (2/31P) has not shown
any relapse in virus replication since week 22. In contrast,
viral replication in the cerebral compartment of the morphine-
exposed macaques presented a completely different picture.
The Group A macaques (1/04L, 1/42N and 1/28Q) showed
vigorous replication in the cerebral compartment, and all these
monkeys had over 106 viral RNA copies/ml CSF at the time of
necropsy. The other three morphine-exposed animals (Group
B) showed a similar pattern of virus replication as seen in
the controls (Group C). Virus replication in Group B animals
became undetectable within 22 weeks after infection. Ma-
caque 1/56L from Group B showed detectable virus repli-
cation at week 32 post-infection, and viral load increased
throughout the rest of the observation period. This animal was
euthanized at week 51 with a CSF viral load of >106 RNA
copies Eq/ml. The last two animals (1/52N and 1/02N) in this
group showed detectable viral replication from weeks 36 and
40, respectively. These animals remained positive until week
52, with a viral load of <250 RNA copies Eq/ml of CSF. The
peak CSF viral load in Group A was significantly higher than
that found in the corresponding samples from the animals in
Groups B and C (p=0.007), whereas there was no significant
Fig. 3. Cerebrospinal fluid (CSF) viral load in morphine-exposed (A) and control macaques (B). Sequential CSF samples were collected, and viral load was determined
in a real-time RT-PCR assay. The results are presented as RNA copy Eq/ml of plasma. The sensitivity of the assay was 80 RNA copies Eq/ml.
196 R. Kumar et al. / Virology 354 (2006) 192–206difference in the CSF viral loads between Groups B and C
animals (p=0.16).
SIV/17E-Fr and SHIVKU (but not SHIV89.6P) crossed the blood
brain barrier
The presence of a replicating virus was identified in PBMC
and CSF at weeks 2, 4, 8 and 12 and once every 8 weeks
thereafter. The results of differential PCR found in the blood and
in the cerebral compartments are shown in Tables 1 and 2
respectively. All 3 viruses were detectable in the blood at all
times, and therefore there was no selection of the virus in terms
of replication in either the control or the morphine-addicted
animals. The only exception was animal 1/52N, which did not
show any virus at week 56, post-infection. In contrast, only SIV/
17E-Fr DNA was present in the CSF co-culture from both
morphine-addicted and control macaques at week 2, suggesting
that SIV/17E-Fr had crossed the blood brain barrier soon after
infection. Follow-up analyses showed that SHIVKU crossed the
blood brain barrier within 8 weeks in the morphine-exposed
macaques, whereas it did not cross blood brain barrier for
28 weeks in the control animals. Surprisingly, SHIV89.6P could
not be detected in the brain at any time point, suggesting that
this virus was not neuropathogenic.Slow progressor, morphine-exposed and control macaques
developed Env-specific binding antibodies
Sequential plasma samples were tested for the presence
of envelop-specific antibodies in a Con-A ELISA. The re-
sults of anti-envelope antibodies against different viruses are
shown in Table 3. Among morphine-exposed macaques, the
Group A animals that were euthanized at weeks 18, 19
and 20 did not develop binding antibodies against either
of the viral envelopes. However, macaque 1/56L (eutha-
nized at week 51) and 1/02N developed moderate levels of
binding antibodies. The 6th macaque (1/52N) in the mor-
phine group (showing excellent CD4 recovery and virus
control) developed maximum envelope-specific binding an-
tibodies. Generally, the slow-progressor morphine-exposed
animals (Group B) developed maximum antibodies against
the SHIV89.6P envelope followed by antibodies against the
SHIVKU and SIV/17E-Fr envelopes. Three control macaques
also developed binding antibodies against all 3 viral enve-
lopes. These macaques developed a comparable level of an-
tibodies against SHIVKU and SHIV89.6P, whereas binding
antibody titer against SIV/17E-Fr was relatively lower. The
antibody levels were generally correlated with level of CD4
recovery.
Table 1
Differential viral distribution in blood of morphine-exposed and control macaques infected with virus cocktail
SHIVKU SHIV89.6P SIV/17E-Fr
W2 W4 W8 W12 W20 W28 W36 W44 W56 W2 W4 W8 W12 W20 W28 W36 W44 W56 W2 W4 W8 W12 W20 W28 W36 W44 W56
Morphine
1/02N + a + + + + + + + + + + + + + + + + + + + + + + + + + +
1/04L + + + + Db + + + + D + + + + D
1/28Q + + + + D + + + + D + + + + D
1/42N + + + + + D + + + + + D + + + + + D
1/52N + + + + + + + + − c + + + + + + + + − + + + + + + + + −
1/56L + + + + + + + + D + + + + + + + + D + + + + + + + + D
Control
2/31P + + + + + + + + + + + + + + + + + + + + + + + + + + +
2/02P + + + + + + + + + + + + + + + + + + + + + + + + + + +
2/AC42 + + + + + + + + + + + + + + + + + − + + + + + + + + +
a A sample was designated positive when PCR product was obtained at least in 1 of 3 independent PCR reactions.
b Dead.
c The sample was designated negative when it did not amplify in any of three independent PCR reactions.
Table 2
Differential viral distribution in cerebrospinal fluid of morphine-exposed and control macaques
SHIVKU SHIV89.6P SIV/17E-Fr
W2 W4 W8 W12 W20 W28 W36 W44 W56 W2 W4 W8 W12 W20 W28 W36 W44 W56 W2 W4 W8 W12 W20 W28 W36 W44 W56
Morphine
1/02N NDa ND − b + c + + + + + ND ND − − − − − − − ND ND + + + + + + +
1/04L − − − + Dd − − − − D + + + + D
1/28Q − ND + + D − ND − − D + ND + + D
1/42N − − + − + D − − − − − D + + + + + D
1/52N − − + + + + + + − − − − − − − − − − + + + + + + + + +
1/56L − − + + + + + + D − − − − − − − − − + + + + + + + + D
Control
2/31P − − − − − + + + + − − − − − − − − − + + + + + + + + +
2/02P − − − − − + + + + − − − − − − − − − + + + + + + + + +
2/AC42 − − − − − + + + + − − − − − − − − − + + + + + + + + +
a Not done.
b The sample was designated negative when it did not amplify in any of three independent PCR reactions.
c A sample was designated positive when PCR product was obtained at least in 1 of 3 independent PCR reactions.
d Dead.
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198 R. Kumar et al. / Virology 354 (2006) 192–206Slow progressor, morphine-exposed and control macaques
developed neutralizing antibodies against 3 pathogenic viruses
The neutralizing antibody titers were measured once every
4 or 8 weeks throughout the observation period (Table 4).
The Group A rapid progressor did not develop neutralizing
antibodies against any of the pathogenic viruses, whereas the
animals in the other groups did. Among morphine-exposed
animals, the SHIV89.6P-specific neutralizing antibody titer was
generally higher than the antibody levels against two other
viruses. Among control animals, the neutralizing antibody titers
were almost comparable against SHIVKU and SHIV89.6P,
whereas levels of SIV/17E-Fr-specific neutralizing antibodies
were lower.
Slow progressor, morphine-exposed and control macaques
developed cell-mediated immune responses
The cell-mediated immune responses in morphine-exposed
and control macaques were measured by determining the
numbers of IFN-γ and IL-4 secreting PBMC. The Th1/Th2
response was calculated by dividing the number of IFN-γ
secreting cells with that of the number of IL-4 secreting cells.
These results are shown in Tables 5 and 6, respectively. The 3
rapid progressors in the morphine-exposed group did not
develop any response, whereas the 2 other morphine-exposed
animals (1/56L and 1/02N) developed a poor to moderate
response. The 6th morphine-exposed animal (1/52N) developed
the best response among all 6 animals, and that might have
contributed to the control of viral replication. All three controls
also developed weak to moderate type-1 and type-2 responses.
The Th1/Th2 ratio was >1 at week 4 in 2 slow progressor,
morphine-exposed animals, whereas 1 macaque (1/56L) had a
Th1/Th2 ratio of <1; this animal succumbed to SHIV/SIV-
induced AIDS at week 51, post-infection. The other 2 slow
progressors were still alive at week 56. All 3 controls had a Th1/
Th2 ratio of ≥1 at week 4, post-infection.
Clinical disease in morphine-exposed macaques were
associated with elevated MCP-1
The MCP-1 level was monitored in morphine-exposed
macaques before initiation of morphine injection and at 3
other time points after initiation of morphine administration but
before virus infection. The results of this experiment are shown
in Table 7. The pretreatment value in these animals ranged
between 7.1 and 29.6 pg/ml of plasma. The morphine treatment
did not cause any substantial change in MCP-1 levels as 5 of 6
macaques did not show 2-fold increase at any time points tested.
Only macaque 1/02N showed 2.7-fold increase 15 weeks after
initiation of morphine administration. However, MCP-1
decreased to pretreatment level at the time of virus infection.
After virus inoculation, the MCP-1 increased almost 5-fold in 4
of the 6 morphine-exposed macaques and these animals were
euthanized with 3 of them with neurological symptoms. Two
morphine-exposed survivors did not show a significant change
in MCP-1 level except 2 time points when 1/02 N showed 2.76-
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Fig. 4. Detection of C77G polymorphism in morphine-exposed and SIV/SHIV-
infected rhesus macaques. A 137 bp product was amplified within exon 1 of mu-
opioid receptor using PBMC DNA as template. The PCR product was purified
and digested with Fnu4HI. The digested product was visualized on a 3% agarose
gel. The monkeys' names are mentioned on the top. The positive control G77
provides 2 bands after digestion, whereas C77 positive controls are not digested
with Fnu4HI, and therefore give one band on the gel. The presence of two lower
bands indicates 2 G77 allele whereas 1 higher band indicates presence of 2 C
alleles. A triple band pattern indicates that one allele is G77 whereas other allele
contains C77.
199R. Kumar et al. / Virology 354 (2006) 192–206and 2.1-fold increase at weeks 20 and 40, post-infection,
respectively. One of the 3 control animals (2/02P) showed
significant MCP-1 increase at weeks 40 and 56, suggesting
possible onset of clinical disease.
Lack of correlation between C77GP SNP in mu-opioid
receptor and rapid disease progression
C77G single nucleotide polymorphism (SNP) in rhesus mu-
opioid receptor (MOR) has been identified that correspond to
A118G SNP in human MOR. These SNPs have been implicated
in beta-endorphin affinity for the receptor, lower blood cortisol
levels and higher aggressive threat behavior in monkeys (Bond
et al., 1998; Wand et al., 2002; Miller et al., 2001, 2004). We
wanted to determine whether this SNP was involved in rapid
disease progression. Two rapid progressor macaques (1/04L and
1/42N) were found to have homozygous G77 allele whereas 3rd
rapid progressor (1/28Q) had homozygous C77 allele. On the
other hand, 2 of 3 slow progressors had heterozygous C77 and
G77 alleles whereas 3rd slow progressor (1/52N) had homo-
zygous G77 alleles (Fig. 4). Therefore, there was no correlation
observed between C77G alleles MOR and disease progression.
Discussion
In this report, we have unequivocally shown that chronic
morphine exposure has a deleterious effect on virus replication
as well as on the onset of SIV/SHIV-induced AIDS. Three of the
6 morphine-exposed macaques succumbed to SIV/SHIV-
induced AIDS within 20 weeks after infection, whereas the
4th macaques developed the disease and succumbed to AIDS-
related complications at week 51, after infection. None of the
control animals had developed AIDS within 56 weeks after
infection. This is the first report describing accelerated disease
progression in an animal model of HIV/AIDS. The previously
reported human studies on opiate abuse and HIV/AIDS have
resulted into both survival advantages as well as lower survival
rate (Alcabes and Friedland, 1995; Kaslow et al., 1989; Munoz
et al., 1992; Montella et al., 1992; Margolick et al., 1992;
Table 5
Virus-specific T cells in morphine-exposed and control monkeys infected with virus cocktail
Macaques Virus specific T cells/million PBMCa
Cells secreting IFN-γ (type-1 response) Cells secreting IL-4 (type-2 response)
4 8 12 16 20 32 40 48 52 4 8 12 16 20 32 40 48 52
Morphine
1/02N 60 140 210 290 310 265 280 230 235 35 90 140 135 175 190 110 145 160
1/04L 0 0 0 0 0 b 0 0 0 0 0 b
1/28Q 0 0 0 0 0 c 0 0 0 0 0 c
1/42N 0 0 0 0 0 d 0 0 0 0 0 d
1/52N 110 470 510 590 540 675 690 640 635 75 145 210 290 320 275 245 310 285
1/56L 80 220 230 245 290 270 225 210 165 e 110 190 180 170 205 210 260 245 265 e
Control
2/31P 240 270 275 340 310 265 290 335 350 90 135 190 145 110 175 145 155 190
2/02P 210 220 290 165 110 190 175 165 210 85 170 215 175 190 115 165 175 145
2/AC42 110 190 240 275 210 225 260 235 220 110 180 165 135 210 235 175 180 180
a 100,000 cells were incubated in 50 μl UV-irradiated and heat-inactivated virus cocktail, and the numbers shown here represent virus-specific cells. The numbers
were calculated by subtracting number of spots in control wells from the number of spots in virus-activated wells.
b Values obtained at the time of necropsy (week 18).
c Values obtained at the time of necropsy (week 19).
d Values obtained at the time of necropsy (week 20).
e Values obtained at the time of necropsy (week 51).
200 R. Kumar et al. / Virology 354 (2006) 192–206Selwyn et al., 1992). However, several of these studies failed to
distinguish between different substances of abuse or to take into
account the viral load in the plasma, which might have
influenced the eventual outcome of the study (Donahoe, 2004).
The earlier studies in the macaque model have also provided
conflicting results. In some studies, the morphine dependence
increased the virus replication in SIV-infected macaques
(Chuang et al., 1993b; Suzuki et al., 2002), while in another
study, the morphine dependence conferred beneficial effects
(Donahoe et al., 1993). However, both studies had some
inherent problems. The first set of studies used only limited
number of animals, and the increase in virus replication was not
observed for at least 17 months after infection; the study by
Donahoe and coworkers did not have internal controls. The
delay in the adverse effect of morphine on virus replication inTable 6
Th1/Th2 ratio in morphine-exposed and control macaques infected with virus
cocktail
Macaques Th1/Th2 ratio
W4 W8 W12 W16 W20 W32 W40 W48 W52
Morphine
1/02N 1.71 1.55 1.50 2.15 1.77 1.39 2.54 1.58 1.47
1/04L N/A N/A N/A N/A N/A
1/28Q N/A N/A N/A N/A N/A
1/42N N/A N/A N/A N/A N/A
1/52N 1.47 3.24 2.43 2.03 1.69 2.45 2.51 2.06 2.23
1/56L 0.72 1.16 1.28 1.44 1.41 1.29 0.87 0.81 0.62
Control
2/31P 2.67 2.00 1.45 2.34 2.82 1.51 2.00 2.16 1.84
2/02P 2.47 1.29 1.35 0.94 0.58 1.65 1.06 0.94 1.45
2/AC42 1.00 1.06 1.45 2.03 1.00 0.96 1.49 1.31 1.22
N/A, not applicable.the previously reported study (Suzuki et al., 2002) can be
attributed to the choice of virus. The earlier study used
SIVmac239, which causes CD4 loss only during late stages. In
the absence of CD4 loss, it always remained a possibility that
morphine-exposed animals might have generated some immune
response that controlled the virus for 18 months. This model
does not replicate natural HIV infection, wherein infected
individuals undergo continuous CD4 loss. The beneficial effect
of morphine can be again attributed to the choice of the
challenge virus. SIVsmm has been shown to cause productive
infection in rhesus macaques, but virus replication becomes
undetectable in half of the animals within 19 weeks (Fultz et al.,
1986). In view of shortcomings associated with earlier studies,
we developed a model of morphine addiction and HIV/AIDS
that utilizes infection with a mixture of 2 SHIVs and a
neuropathogenic SIV. We have shown that macaques infected
with 3 viruses lose CD4+ T cell. However, the loss was more
rapid than that seen in humans infected with HIV. This model
enabled us to demonstrate that peak virus replication in
morphine-exposed and control macaques was similar, but
viral loads in both the cerebral and the blood compartment
were significantly higher, 4 and 6 weeks after infection,
respectively (Kumar et al., 2004).
The morphine-exposed and control macaques showed a
precipitous loss of CD4+ T cells. However, the CD4 recovery
pattern was completely different in the two groups. Only 1 of 6
morphine-exposed macaques showed significant recovery,
whereas two-thirds of the control animals experienced sub-
stantial CD4 recovery. The difference in CD4 profile could be
one of the reasons that might have accelerated the onset of
clinical disease in 2/3 of the morphine-exposed macaques. It has
been previously shown that many HIV-infected long-term non-
progressors and SHIV-infected slow progressor macaques do
not lose circulating CD4+ T cells for a long time (Comar et al.,
Table 7
Monocyte chemoattractant protein-1 (MCP-1) in plasma of morphine-exposed and control macaques infected with SIV/SHIV cocktail
Group Macaque MCP-1 concentration (pg/ml) in monkey plasma at weeks a
−20 −5 0 4 12 20 28 40 56
Morphine 1/28Q 18.5 24.33 (1.3) b 27.01 (1.46) 54.76 (2.96) 70.31 (3.8) 268.82 (14.53) c
1/42N 27.0 51.02 (1.89) 29.55 (1.09) 36.63 (1.36) 133.92 (4.96) 93.06 (3.45) d
1/04L 7.1 7.08 (1) 7.08 (1) 15.2 (2.14) 18.49 (2.6) 40.99 (5.77) e
1/02N 21.5 58.39 (2.72) 21.51 (1) 36.63 (1.7) 38.84 (1.81) 59.28 (2.76) 15.2 (0.71) 45.13 (2.1) 34.35 (1.6)
1/52N 29.6 15.2 (0.51) 34.35 (1.16) 38.84 (1.31) 47.13 (1.59) 45.13 (1.52) 36.63 (1.23) 36.63 (1.24) 40.99 (1.38)
1/56L 21.5 21.51 (1) 24.33 (1.13) 18.49 (0.86) 54.76 (2.54) 61.91 (2.88) 67.01 (3.17) 102.79 (4.78) 49.09 (2.28) f
Control 2/AC42 21.5 43.08 (2) 54.76 (2.55) 38.84 (1.81) 21.51 (1) 34.35 (1.6) 38.84 (1.79)
2/02P 11.5 15.2 (1.32) 15.2 (1.32) 18.49 (1.61) 24.33 (2.12) 49.09 (4.27) 78.24 (6.8)
2/31P 45.1 60.16 (1.3) 24.33 (0.54) 52.91 (1.17) 24.33 (0.54) 45.13 (1) 49.09 (1.09)
a The time of virus infection was considered as week 0. Week −20 represents initiation of morphine treatment.
b MCP-1 concentration in plasma is shown in pg/ml, and value in parentheses represents fold difference from first number.
c The result also represents necropsy value as plasma was collected at the time of necropsy.
d The MCP-1 concentration was measured in necropsy plasma collected at week 19.
e The MCP-1 concentration was measured in necropsy plasma collected at week 18.
f The MCP-1 concentration was measured in necropsy plasma collected at week 51.
201R. Kumar et al. / Virology 354 (2006) 192–2061997; Kumar et al., 2001; Silverstein et al., 2000). This study
also showed that some of the morphine-exposed macaques (1/6)
displayed remarkable CD4 recovery, which turned out to be
higher than the pre-infection level CD4 count. This type of
recovery was not even seen in any of the control animals. Two
different CD4 profiles in morphine-exposed macaques can also
be attributed as a possible reason for the different outcomes seen
in the earlier studies (Suzuki et al., 2002; Donahoe et al., 1993).
Morphine itself has been shown to cause decrease in CD4+ T
cells in macaques (Carr and France, 1993a, 1993b). We did not
see any significant CD4+ T-cell loss in morphine-exposed
macaques before infection. However, the CD4+ T-cell loss was
significantly higher in morphine-exposed animals compared to
that in control animals at week 2, post-infection (Kumar et al.,
2004). This more pronounced loss in morphine-exposed
animals can be attributed to cumulative effect of morphine
and virus. We do not have any information regarding MHC type
in these animals, but it is likely that genetic background might
have been a contributing factor towards the development of
clinical disease. This phenomenon has been seen among HIV-
infected individuals, where HLA types were found to be directly
related with HIV susceptibility/resistance (Flores-Villanueva
et al., 2003; Hendel et al., 1999).
Another reason for accelerated disease progression in
morphine-exposed macaques might be attributable to the lack
of development of the inferior/crippled immune response. The
Group A animals did not develop cellular or humoral immune
responses, and they succumbed to SIV/SHIV-induced AIDS
within 20 weeks. Morphine-exposed slow progressors and
control macaques developed both cellular and humoral immune
responses. There was no direct correlation between eventual
CD4 recovery and level of immune responses. Macaques 1/02N
and 1/56L did not show significant CD4 recovery, but they
developed both cellular and humoral immune responses.
However, these responses were slightly lower than those seen
in macaque 1/52N, which showed remarkable CD4 recovery.
Likewise, 3 controls (1 with CD4 recovery and 2 without)
developed both cellular and humoral immune responses. Thelack of correlation between CD4 counts and immune responses
can be attributed to the requirement of no or only a few CD4+ T
cells that were essential for the induction and maintenance of
appropriate immune responses (Wang et al., 2001; Seizer et al.,
2005). Our study offered, however, the possibility of finding a
correlation between the Th1/Th2 ratio and the onset of disease
in slow progressor, morphine-exposed and control animals. Of 6
Groups B and C animals, only 1/56L had a Th1/Th2 ratio of <1
at week 4, post-infection, and this animal succumbed to SIV/
SHIV-induced AIDS at week 51. The other 5 animals that had a
Th1/Th2 ratio of >1 were still alive at the end of the 56-week
observation period. A long-term follow-up of these animals will
determine whether there is a direct correlation between Th1/Th2
ratio and disease onset. The Th1/Th2 shift has also been
implicated in disease progression among HIV-infected humans
(Clerici and Shearer, 1994) and SIV-infected macaques
(Benveniste et al., 1996). Furthermore, a balanced Th/Th2
ratio has been associated with long-term non-progression
among HIV-infected individuals (Imami et al., 2002). The
morphine-exposed animals also showed a trend of a lower Th1/
Th2 ratio at week 4, although the difference in comparison to
control animals was not significant. Opiates are known to
induce a predominant Th2 environment (Roy et al., 2001,
2004). It is possible that such an environment could have helped
in the induction of a higher Th2 response in morphine-exposed
macaques. A long-term follow-up of these animals will
determine whether there is a direct correlation between Th1/
Th2 ratio and onset of disease.
Group A morphine-exposed macaques showed significantly
higher virus replication in the cerebral compartment than was
seen in the Groups B and C macaques. Furthermore, high virus
replication in the cerebral compartment preceded the onset of
clinical disease in macaque 1/56L. SIV/17E-Fr (one of the
pathogenic viruses used to initiate infection) has been shown to
cause the development of SIV-mediated encephalitis (Zink et
al., 1997, 1998, 1999, 2001; Mankowski et al., 2004). The
higher virus replication in the cerebral compartment in the
present study can be attributed to the morphine-mediated
202 R. Kumar et al. / Virology 354 (2006) 192–206increase in TNF-α production by microglia that has also been
previously implicated in increased viral replication in promo-
nocyte line (Peterson et al., 1994, 1998). Furthermore, mor-
phine has also been shown to potentiate apoptosis and the
release of various cytokines by astrocytes and neurons that may
eventually increase the incidence of HIV-associated dementia
(HAD) (Gurwell et al., 2001; El Hage et al., 2005). This was
confirmed in this study where most of the morphine-exposed
macaques developed neurological symptoms.
The cerebral compartment of morphine-exposed macaques
turned out to be a preferential target for SIV/17E-Fr and
SHIVKU replication. The SIV/17E-Fr crossed the blood brain
barrier (BBB) within 2 weeks in both morphine-exposed and
control macaques. However, while SHIVKU crossed the BBB
within 8 weeks in morphine-exposed macaques, it crossed the
BBB within 28 weeks in control macaques. The systemic
immune response did not seem to play any role in the
migration of the virus from the blood to the cerebral com-
partment. Macaque 1/52N (Group B; slow progressor and
morphine-exposed) developed better antibody and cellular
immune responses than those seen in any of the controls, but
this did not cause a delay in the migration of SHIVKU from
the systemic to the cerebral compartment. The exact reason
for this preferential crossover in morphine-exposed macaques
is not known, but chronic morphine administration is known
to induce inflammatory responses by disrupting IL-1β mod-
ulation of the hypothalamic–pituitary–adrenal axis (HPA)
(House et al., 2001), and that might have played some role
in the early BBB crossing of SHIVKU in morphine-exposed
macaques.
Morphine is known to increase HIV replication in monocyte/
macrophages (Guo et al., 2002; Li et al., 2003; Ho et al., 2003;
Peterson et al., 1994). Furthermore, morphine is also known to
modulate monocyte migration (Singhal et al., 1996; Hatsukari et
al., 2006) and MCP-1 is thought to be one of the factors
responsible for monocyte migration (Maslin et al., 2005; Kim et
al., 2006). MCP-1 has been implicated in HIV encephalitis and
also in SIV-associated CNS complications (Conant et al., 1998;
Kelder et al., 1998; McManus et al., 2000; Sanders et al., 1998;
Sasseville et al., 1996; Zink et al., 2001). In the present study,
4 morphine-exposed monkeys developed clinical disease du-
ring observation period. These animals showed 11- to 20-
fold increase in monocyte number as well as 4.8- to 14.5-fold
increase in MCP-1 concentration in plasma, suggesting that
increased MCP-1 might be responsible for infected monocyte
migration to brain (as evident by high viral loads in CSF
compartment) and eventual neurological symptoms in 3 of 4
macaques.
In summary, we have shown that chronic morphine exposure
causes higher virus replication in the systemic and cerebral
compartments, accelerated crossover of one of the pathogenic
viruses into the cerebral compartment and speedy onset of SIV/
SHIV-induced AIDS in Indian rhesus macaques. Development
of the systemic immune response also coincided with at least a
temporary suppression of virus replication in the brain.
However, these immune responses did not affect the viral
crossover from the systemic to the cerebral compartment.Materials and methods
Viruses
SHIVKU-1B was derived from non-pathogenic SHIV-4 by
passaging into pigtailed macaques (Joag et al., 1996).
SHIV89.6P and SIV/17E-Fr were kindly provided by Profs. N.
Letvin, Boston, MA and J. Clements, Baltimore, MD, res-
pectively (Reimann et al., 1996a; Flaherty et al., 1997). Stock
preparations of these viruses were propagated in macaque
PBMC. Infectivity of stocks of the three viruses was assayed in
C8166 cell culture and had titers of 104 (SHIVKU), 1.4×10
4
(SHIV89.6P) and 4.3×10
4 TCID50/ml (SIV/17E-Fr).
Establishment of chronic morphine exposure and infection of
animals
Nine 1.5- to 2.5-year-old male rhesus macaques (Macaca
mulatta) were obtained from the Caribbean Research Primate
Center and maintained in the AAALAC-approved Animal
Facility at the University of Puerto Rico Medical School. The
body weight of these animals ranged between 3 and 4.2 kg at
the commencement of the study. The animals were tested for
tuberculosis, simian T-cell leukemia virus type-1 and simian
retrovirus and found negative in all these tests. The
experimental protocol was approved by the Institutional
Animal Care and Use Committee, and the research was
performed in accordance with the Guide for the Care and
Use of Laboratory Animals. These animals were divided into
two groups (morphine-exposed and control) of 6 and 3,
respectively. The chronic morphine exposure was established
by injecting (intramuscularly) increasing doses of morphine
(1 to 5 mg/kg of body weight over a 2-week period) every
8 h (7:00 AM, 3:00 PM and 11:00 PM). Morphine was
administered for an additional 18 weeks before virus infection
and also continued throughout the study period. Six
morphine-exposed and three control animals were infected
with SHIVKU-1B, SHIV89.6P and SIV/17E-Fr at week 20 after
the initiation of the morphine injection (also known as week
0, post-infection, and referred to as such hereafter). The
animals were injected intravenously with 2 ml inoculum
containing 104 50% tissue culture infectious doses (TCID50)
of each virus.
Flow cytometry
Lymphocyte subset cell profiles were determined by staining
for CD3, CD4 and CD8 cell surface markers using the whole
blood lysis technique (Wyand et al., 1999). Briefly, 10 μl of the
antibody mix against CD3, CD4 and CD8 (Becton Dickinson)
was added to 100 μl of whole blood and incubated for 1 h in the
dark. Lysing solution (Becton Dickinson) was then added, and
the samples were incubated for another 10 min at room
temperature. Stained cells were fixed with 0.5% paraformalde-
hyde and analyzed in a flow cytometer (Becton Dickinson
FACSCalibur). The absolute CD4+ CD8+ T-cell counts were
determined by multiplying the percentage (obtained by flow
203R. Kumar et al. / Virology 354 (2006) 192–206cytometric analysis) with the absolute lymphocyte number
obtained from a complete blood count.
Viral load measurements
Cell-associated viral loads in blood and brain were
determined in an infectious cell assay (Kumar et al., 2001),
and cell-free viral loads in plasma and cerebrospinal fluid (CSF)
were determined using real-time RT-PCR (Amara et al., 2001).
The viral RNA copy number in monkey samples was
determined by comparison with an external standard curve
consisting of an in vitro transcript representing bases 211–2101
of the SIVMAC239 genome. This assay had a sensitivity of 80
copies/ml of plasma or CSF.
Detection of challenge virus DNA in PBMC and CSF
For the purpose of virus identification in the brain, CSF
was co-cultured with CEMx174 cells for 1 week. Proviral
DNAwas extracted from the PBMC and CSF-CEM co-culture,
using the QIAamp DNA Blood Kit (QIAGEN, Inc., Valencia,
California). Total cellular DNA (extracted from different
animals) was screened for the presence of different proviral
DNA by PCR using primers specific for the envelope
sequences of SHIVKU, SHIV89.6P and SIV/17E-Fr. The
sequence of the primers for 1st and 2nd round amplifications,
the location of the primers in the virus genome and the
expected size of the PCR products have been previously
described (Kumar et al., 2002). Briefly, 0.5 μg of genomic
DNA was used in the PCR mixture containing 4 mM MgCl2,
200 μM each of the four deoxynucleoside triphosphates, 100
pM each of the oligonucleotide primers and 2.5 U of Taq
polymerase (Perkin-Elmer Cetus, Norwalk, CN). The template
was denatured at 95 °C for 3 min, and PCR amplification
performed with an automated DNA thermal cycler (Perkin-
Elmer Cetus) for 35 cycles of denaturation at 92 °C for 1 min;
annealing at 55 °C for 1 min; and primer extension at 72 °C for
3 min. The reaction was completed after 10 min of primer
extension at 72 °C. Two microliters of the resultant product was
used in the 2nd round of PCR, using previously described
primers (Kumar et al., 2002) and conditions (as described above
for the 1st round.). Following the second round of amplifica-
tion, a 5-μl aliquot was electrophoresed on a 1.5% agarose gel,
and the bands were visualized by staining with ethidium
bromide. Three independent PCR reactions were performed
separately for each sample, and the sample was considered
positive for a given virus with signal in any of the 3 independent
PCR reactions.
Measurement of binding antibody titer against viral envelope
Plasma samples from both the morphine-exposed and the
control monkeys were analyzed for their reactivity to native
viral glycoprotein in a concanavalin-A (Con-A) ELISA,
developed by Robinson et al. (1990) and adapted to the
macaque system (Cole et al., 1997; Kumar et al., 2000).
Preparation of SHIVKU, SHIV89.6P, or SIV/17E-Fr, purifiedby density gradient centrifugation and disrupted with 1%
triton X-100, was used as source of viral glycoproteins.
Immulon II microtiter plates (Dynatech Laboratories) were
incubated with 5 μg of Con-A (Sigma, St. Louis, MO) per
well in 100 μl of phosphate-buffered saline (PBS, pH 7.2) for
90 min at 37 °C and then washed twice with Normal Saline
Tween (NST—0.85% NaCl and 0.1% Tween-20). Three
hundred nanograms of viral proteins in 100 μl of PBS was
then added to each well, and the plate was again incubated at
37 °C for 90 min. The plate was again washed twice with
NST and blocked with R-10 by adding 300 μl of R-10 into
each well. After the blocking solution was removed, 100 μl of
serial two-fold diluted monkey plasma was added to each
well in duplicate and the plate was again incubated at 37 °C
for 90 min. The plate was washed again, thrice, with NST,
and 100 μl of peroxidase-conjugated anti-monkey IgG
(Sigma-diluted 1:10,000 in PBS containing 1% FBS) was
added. The plate was again incubated at 37 °C followed by 4
washings with NST. The reaction was developed by adding
100 μl of citrate–phosphate buffer (pH 5.0) containing
0.5 mg/ml of orthophenylenediamine (OPD) and 0.4 μl/ml
of 30% H2O2. The reaction was stopped by adding 50 μl of
1 N HCl, and optical density was read in a plate reader
(Dynatech) at 490 nm wavelength. Endpoint titers were
determined by the last dilution, whose OD was twice that of
normal monkey plasma at 1:1000 dilution or an OD of 0.1,
whichever value was greater.
Measurement of the neutralizing antibody titer against SHIV
and SIV
The neutralizing antibody titer in plasma was determined as
described previously (Kumar et al., 2000). Briefly, two-fold
serial dilutions of heat-inactivated plasma in R-10 were
prepared in quadruplicate in round-bottom 96-well plates, and
16 TCID50 of the test virus (SHIVKU, SHIV89.6P or SIV/17E-
Fr) was added to each well. Plates were incubated 1 h at 37 °C,
and 104 C-8166 cells were added to each well. Each well was
scored individually for the virus-induced cytopathic effect after
a 7-day incubation at 37 °C. The endpoint titer was defined by
the ability of a plasma dilution to neutralize the virus in all 4
wells.
ELISPOT assays
Cellular immune responses were monitored by measuring
IFN-γ and the IL-4 secretion of morphine-exposed and control
monkeys' PBMC, stimulated with a mixture of UV-irradiated
and heat-inactivated SHIVKU, SHIV89.6P or SIV/17E-Fr (UV-
HI virus cocktail). The UV-HI virus cocktail was prepared by
mixing an equal volume of SHIVKU, SHIV89.6P or SIV/17E-Fr
followed by UV irradiation for 1 h and heat inactivation at 56 °C
for 3 h. The control stimulant was prepared by processing R-10
(RPMI-1640 containing 10% fetal bovine serum) in the similar
manner. The ELISPOT assay was performed using IFN-γ and
IL-4 ELISPOT kits that were procured from U-CyTech
Biosciences, Utrecht, Netherlands. The assay was performed
204 R. Kumar et al. / Virology 354 (2006) 192–206using the manufacturer's protocol except that the PBMCs were
incubated for 6 h at 37 °C in a humidified atmosphere
containing 5% CO2. One hundred thousand PBMCs were
stimulated with 50 μl of UV-HI virus cocktail in duplicate. The
ELISPOTs were counted by using an automated AID EliSPot
reader system (Strassberg, Germany). The results are expressed
as spot forming cells/106 PBMC which were obtained by
subtracting the number of spots in the control wells from the
number of spots in the UV-HI virus cocktail-stimulated wells.
The control numbers were obtained by incubating 105 of PBMC
with 50 μl of control stimulant. The Th1/Th2 ratio was
calculated by dividing the number of IFN-γ secreting cells by
the number of IL-4 secreting cells.
Determination of plasma MCP-1 using luminex technology
Monocyte chemoattractant protein-1 (MCP-1) was measured
in plasma as part of simultaneous detection of multiple
cytokines and chemokines using luminex technology (Giave-
doni, 2005). MCP-1 antibody pair was received as gift from
Upstate USA, Inc (Chicago, IL). The MCP-1 was measured at
weeks −20, −5, 0, 4, 12, 20, 28, 40 and 56 in morphine-exposed
macaques and at weeks 0, 4, 12, 20, 28, 40 and 56 in control
macaques. The results are presented as concentration in pg/ml
and also as fold difference compared to normal values. More
than 2-fold difference in plasma MCP-1 was considered
significant.
Detection of MOR C77G SNP in morphine-exposed rhesus
macaques
Morphine-exposed and SIV/SHIV inoculated animals were
analyzed for presence of C77G single nucleotide polymorph-
ism (SNP) following a previously published protocol (Miller
et al., 2004). Briefly, a 137 base fragment in mu-opioid
receptor was amplified from PBMC DNA. The PCR product
was purified using QiaquickTM PCR clean-up kit (Qiagen Inc.
Valencia, CA, USA), and digested with Fnu4HI (New England
Biolabs, Beverly, MA, USA) for 1 h. The samples were
electrophoresed on 3% agarose gels containing ethidium
bromide. The gels were visualized under UV transillumination
(Fig. 4).
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